Polymorphisms of SLC22A9 (hOAT7) in Korean Females with Osteoporosis

Seong Kyu Ahn, Chang Kook Suh, and Seok Ho Cha

Departments of 1Tropical Medicine and Parasitology, 2Physiology and Biophysics, College of Medicine, Inha University, Incheon 400-712, Korea

Among solute carrier proteins, the organic anion transporters (OATs) play an important role for the elimination or reabsorption of endogenous and exogenous negatively charged anionic compounds. Among OATs, SLC22A9 (hOAT7) transports estrone sulfate with high affinity. The net decrease of estrogen, especially in post-menopausal women induces rapid bone loss. The present study was performed to search the SNP within exon regions of SLC22A9 in Korean females with osteoporosis. Fifty healthy controls and 50 osteoporosis patients were screened for the genetic polymorphism in the coding region of SLC22A9 using GC-clamped PCR and denaturing gradient gel electrophoresis (DGGE). Six SNPs were found on the SLC22A9 gene from Korean women with/without osteoporosis. The SNPs were located as follows: two SNPs in the osteoporosis group (A645G and T1277C), three SNPs in the control group (G1449T, C1467T and C1487T) and one SNP in both the osteoporosis and control groups (G767A). The G767A, T1277C and C1487T SNPs result in an amino acid substitution, from synonymous vs nonsynonymous substitution arginine to glutamine (R256Q), phenylalanine to serine (F426S) and proline to leucine (P496L), respectively. The Km values and Vmax of the wild type, R256Q, P496L and F426S were 8.84, 8.87, 9.83 and 12.74 μM, and 1.97, 1.96, 2.06 and 1.55 pmol/oocyte/h, respectively. The present study demonstrates that the SLC22A9 variant F426S is causing inter-individual variation that is leading to the differences in transport of the steroid sulfate conjugate (estrone sulfate) and, therefore this could be used as a marker for certain disease including osteoporosis.

Key Words: SLC22A9, Polymorphism, Osteoporosis, Estrone sulfate, Denaturing gradient gel electrophoresis, GC-clamp

INTRODUCTION

Bone is a very complicated tissue in which formation and resorption occur by a bone remodeling process. The loss of bone mass occurs in osteoporosis. Due to low bone mass, there is increased bone fracture of hip, shoulder, wrist and spine. Estrogen is the key hormone for maintaining bone mass. It has been thought that estrogen deficiency is the major cause of age-related bone loss in humans [1]. Osteoporosis is initiated by the failure to acquire the optimal peak of bone mass during growth and/or to maintain bone mass in later years [2]. The rapid loss of bone mass occurs in post-menopausal women, mainly due to the net decrease of estrogen [2]. The estrogen deficiency also induces an imbalance in bone remodeling, accelerates the loss of bone mass increasing fracture risk [3,4]. Therefore, estrogen deficiency can be characterized by high bone turnover with enhanced osteoclastic bone resorption. The important factor in determining bone density and bone turnover in humans is circulating estradiol [5-9]. The most abundant estrogen precursor in circulation is the sulfate conjugate form of estrogen such as estrone sulfate. The amount of this conjugated form of estrogen is several fold higher than that of unconjugated estrogens [10-12]. In addition, the estrone sulfate is well known as the substrate of organic solute carriers such as SLC22A8 (hOAT3), SLC22A9 (hOAT7) and SLC22A11 (hOAT4) [13-15].

The single non-synonymous SNPs (nsSNPs) contribute commonly to the functional diversity on encoded proteins in humans. It appears that nsSNP often lead to unexpected responses to drugs and changes in the susceptibility to disease [16]. A number of reports indicated that nsSNPs affect the functional roles of certain proteins in gene regulation by altering DNA and transcription factor binding and/or by affecting signal transduction [17-19].

ABBREVIATIONS: SLC, solute carrier; OAT, organic anion transporter; DGGE, denaturing gradient gel electrophoresis; SNP, single nucleotide polymorphism.
In this report we screened SNPs of SLC22A9 in two groups of Korean women: one group had osteoporosis and the second was a normal control group. We then performed a functional analysis of the nsSNP from the osteoporosis group by expression in *Xenopus* oocytes.

**METHODS**

**Materials**

Taq DNA polymerase and polymerase chain reaction (PCR) primers were purchased from ELPIS BIO (Daejeon, Korea) and Bioneer (Daejeon, Korea), respectively. Restriction enzymes, oligo (dT), LA Taq DNA polymerase and dNTPs were bought from TaKaRa Korea Biomedical Co. (Seoul, Korea), and nTTP and m'G(5)ppp(5)G Cap analogue for synthesis of cRNA were purchased from Amer sham Pharmacia Biotech (Sunnyvale, CA, USA). T7 RNA polymerase was bought from Stratagene Cloning Systems Inc. (La Jolla, CA, USA) and RNasin (RNA inhibitor) was purchased from Promega (Madison, WI, USA). Ta DNA mini kit was purchased from Qiagen (Hilden, Germany). [3H]estrone sulfate (53 Ci/mmol) was purchased from NEN Life Science Products, Inc. All other chemicals utilized in this study were insured for the highest purity available from commercial sources.

**Patients**

Blood samples were taken from 50 osteoporosis patients and 50 normal control subjects, which were approved by the Samsung Hospital Institutional Review Board (Cheil General Hospital & Women’s Healthcare Center IRB). All subjects involved in the present study were age matched (40 to 65 years of age). The blood samples were kindly supplied from Dr. Ki Ok Han and also employed previous research [20].

**PCR reaction**

Genomic DNAs were extracted and used as template for the PCR reaction. The PCR primers were approximately 18 mers and were before/after each exon with the GC clamp on the forward or reverse primer [21]. Each PCR reaction mixture (final volume of 12.5 μl) contained 50 ng of isolated genomic DNA, 0.5 mM of dNTP, 10 pmol of each primer and 1 unit of DNA taq polymerase. Amplification was performed using a Takara thermocycler (TP-3000) and the PCR cycling conditions were as follows: an initial denaturation at 94°C for 2 min, followed by 30 or 35 cycles of denaturation at 94°C for 1 min, annealing for 1 min at 55°C to 60°C, and elongation at 72°C for 1 min. The last cycle was followed by an additional elongation step of 72°C for 10 min. For optimal DGGE analysis, amplification was followed by a heteroduplexing step, which includes denaturation at 98°C for 10 min, renaturation for 30 min at the annealing temperature of amplification, and extension at 37°C for 10 min. The amplified products were checked by electrophoresis using 1.5 μl (about 1% of total volume) of each product in a 1% agarose gel stained with 1 μg/ml of ethidium bromide solution. The primer sequences and annealing temperature are shown in Table 1.

**Denaturing gradient gel electrophoresis (DGGE)**

DGGE was performed using a V20-HCDC unit (www.scie-plas.com). PCR products were loaded onto a 230×250 mm, 0.5 mm-thick polyacrylamide gel (acrylamide: bisacrylamide, 37.5:1) containing linear denaturing gradients (100% UF=7 M urea/40% deionized formamide) [22,23]. The percentage of polyacrylamide was 10% and UF solution gradient was from 10% to 70%. Electrophoresis was performed in TAE buffer (40 mM Tris, 20 mM Acetic acid and 1 mM EDTA) at 250 V for 3.5 h at 60°C. The gels were stained with ethidium bromide solution (1 μg/ml) for 10 min and photographed under an UV transilluminator.

**DNA sequencing and variant confirmation**

Samples showing aberrant DGGE bending patterns were used in PCR with non-GC clamp primers prior or after 80 base pairs of the designated site. Samples showing additional heteroduplex bands were subjected to sequencing analysis for the exact determination of the sequence variant.

**Mutant construction**

The wild type SLC22A9 cDNA was obtained by screening a human kidney cDNA library and subcloned to pcDNA 3.1(+). In order to prepare mutants SLC22A9, a modified

| Table 1. Oligonucleotide primers for PCR amplification of the individual exons of the SLC22A9 gene |
|---|---|---|---|
| Exon No. | Forward Primer sequence | Reverse Primer sequence | Annealing Temp. (°C) | Cycle Size (bp) |
| 1 | Clamp-ATC AAC TGT TCA ACC TCA | AGC AGA ACA GAG CCT CT AC | 60 | 30 | 490 |
| 2 | TGG CTT CCT TCT CTT CCA G | Clamp-TGT TCC ATA CAC ACT CAC | 60 | 30 | 191 |
| 3 | Clamp-ACC TGT TTT TGC TCA G | TCC AAA GTG TTG GCT TAC | 60 | 35 | 242 |
| 4 | Clamp-ATC TGT TTT TCT TCC CAG | AGA AGA AAC AAA CTC CTA C | 57 | 35 | 256 |
| 5 | Clamp-TTT TCC TTC TTT GTC AG | AGC TCC CAT CCA GCT CAC | 60 | 30 | 209 |
| 6 | Clamp-TTT CTA TTA TTG TTA AAG | ACA CTG CAT GAA GCT TAC | 60 | 30 | 205 |
| 7 | Clamp-TCC TTT TTA ATC ATC ACA G | ACC TGT GAT CTT TTC TCA C | 60 | 30 | 303 |
| 8 | Clamp-TGT TCT TCC TTT CTC CAG | AGG GCA TAC TTA AGG TCT TGC AC | 60 | 30 | 200 |
| 9 | Clamp-TGC TGT TTT CAC TCA AAG | ACC GGG CTA TTT ACT CAC | 60 | 30 | 290 |
| 10 | TCT TGT TAT TTG TTT TAG | Clamp-CCT TGT TAT TTA TTT TC | 55 | 35 | 227 |

Clamp sequence: CGC CCG CCG CGC CCC GCG CCC GTC CCG CCC CCC CCC CCC CCC G+TAA TAA TAA T.
Table 2. Oligonucleotide primers for mutant construct preparation of the SLC22A9 gene

| Mutant   | Primer name     | Sequence (5’→3’)                                                                 |
|----------|-----------------|----------------------------------------------------------------------------------|
| G767A    | ApaI forward    | aat gac act ggg gcc ctc agc c                                                      |
|          | PvuII reverse   | aca tgc cca aca tat gta aaa gga tgt ccc                                         |
| T1277C   | reverse-1       | aca tgc cca aca tat gta aaa gga tgt ccc                                         |
|          | reverse-2       | aca tgc cca aca tat gta aaa gga tgt ccc                                         |
| Xml1     | reverse-3       | tgg gaa tta cat ttc cat ggg caa cag cag gac cag acg c                              |
| C1487T   | forward-1       | aca tgc cca aca tat gta aaa gga tgt ccc                                         |
|          | forward-2       | aca tgc cca aca tat gta aaa gga tgt ccc                                         |
|          | forward-3       | aca tgc cca aca tat gta aaa gga tgt ccc                                         |

Restriction enzyme sites and mutated nucleotide were denoted by underline and bold capital letters, respectively.

PCR was performed using primer sets containing both mutation and restriction enzyme sites (Table 2). PCR was sequentially performed for 12 cycles with the first primer (0.5 μM, 1 μl) and 12 cycles with the second primer (0.5 μM, 1 μl) and finally 35 cycles with the third primer (10 μM, 1 μl). The PCR product was sub-cloned using the TA cloning vector (Invitrogen) and confirmed its nucleotide sequences. The mutant constructs were prepared by substituting the mutated product into the wild type cDNA of SLC22A9 using the appropriate restriction enzyme digested cDNA.

cRNA synthesis and uptake experiments using Xenopus laevis oocytes

cRNA synthesis and uptake experiments were performed as described previously [24]. The capped cRNAs were synthesized in vitro with T7 polymerase from plasmid cDNAs linearized with Xho I. Defolliculated oocytes were injected with 25 ng of the capped cRNAs and incubated in Barth’s solution (88 mM NaCl, 1 mM KCl, 0.33 mM Ca(NO3)2, 0.4 mM CaCl2, 0.8 mM MgSO4, 2.4 mM NaHCO3, and 10 mM Hepes) containing 50 μg/ml gentamycin and 2.5 mM pyruvate, pH 7.4, at 18°C. After incubation for 2–3 days, uptake experiments were performed at room temperature in ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM Hepes, pH7.4). The uptake reaction was initiated by replacing ND96 solution containing various concentrations of radio-labeled estrone sulfate, which was terminated by the addition of sufficient ice-cold ND96 solution followed by five times washing after 1 h incubation. Oocytes were solubilized with 10% SDS and the radioactivity was determined by scintillation counting.

RESULTS

Genomic organization of human SLC22A9

Using the SLC22A9 cDNA nucleotide sequence, we could find the SLC22A9 genomic DNA was from the NCBI database (gi|56881587:63369670-63410919 Homo sapiens chromosome 11, GRCh38 Primary Assembly). The gene, ~41.3 kb long, is located on chromosome 11q13.1. Using the cloned SLC22A9 with the reported genomic sequence, an alignment of the nucleotide sequence was performed to determine the exon-intron gene organization. The SLC22A9 gene consists of 9 introns and 10 exons (Fig. 1). The size of each exon, intron, and nucleotide sequence of the splice junction is shown in Table 3. The consensus sequences for RNA splicing (gt/ag) are found in the 5’ and 3’ termini for each intron. The translation start codon (ATG) is present in exon 1, and the translation termination codon (TAG) is present in exon 10.

GC-clamp PCR, DGGE assay and screening for sequence variation

The DGGE method was used in order to determine the SNP. The PCR conditions were tested over several annealing temperatures and cycle numbers using normal human chromosomal DNA. The typical patterns of each PCR products with synonymous and non-synonymous mutations found using GC-clamping primer sets separated on 1% agarose gel are presented in Fig. 2A. The representative results of DGGE separated on acrylamide gel using several control samples are shown in Fig. 2B. The results of DGGE showed a single band in the SNP found in exons.

To determine the SNP in Korean osteoporosis patients, 50 blood samples were obtained from osteoporosis and normal subjects and screened. The osteoporosis and control subjects were analyzed, six subjects showed different electrophoretic patterns (Fig. 2C). In general, PCR products were produced in accordance with the different number of bands indicating that a mutation may have occurred.
Fig. 3. Transport activity of the SLC22A9 and its variants. (A) Concentration dependence of estrone sulfate mediated by wild type SLC22A9 and variants in *Xenopus laevis* oocytes. Defolliculated stage VI and V oocytes were injected with 25 ng/oocyte of wild-type and variants cRNAs, and incubated for 3 days in Barth’s solution at 18°C. After three days, [3H] estrone sulfate uptake experiment was performed using various concentrations (25 nM ∼ 50 μM). Each point employs 8 ∼ 10 oocytes and represented mean±standard error of three independent experiments. (B) Eadie-Hofstee plot analysis for determination of Km and Vmax values.

Table 3. Exon-intron boundaries of the SLC22A9 gene

| Exon | Size (bp) | 3' junction | 5' junction | Size (bp) | No. | 3' junction | 5' junction | Exon |
|------|-----------|-------------|-------------|-----------|-----|-------------|-------------|------|
| 1    | 670       | ...CGTGACTGAG | gtaagagct... | 676       | 1   | ...tctttcag | ...         | 2    |
| 2    | 104       | ...TATCGACAG | gatgtgtgt... | 2405      | 2   | ...tgtttcag | ...         | 3    |
| 3    | 155       | ...ATTAGTTAAA | gtagaaca... | 95        | 3   | ...tttttcag | ...         | 4    |
| 4    | 169       | ...TGACCTCAAG | gtagaatgg... | 1582      | 4   | ...cttggcag | ...         | 5    |
| 5    | 124       | ...AACCCTGGAG | gtagctgga... | 6390      | 5   | ...atggtaag | ...         | 6    |
| 6    | 108       | ...CCTTACGAG | gtagcttca... | 24230     | 6   | ...atccacag | ...         | 7    |
| 7    | 201       | ...GTGCCACAAG | gtagaaaag... | 1414      | 7   | ...ctttttcag | ...         | 8    |
| 8    | 109       | ...CCATATCAG | gtacgaacca... | 455       | 8   | ...ccactcaag | ...         | 9    |
| 9    | 204       | ...AGAAAAATGA | gtgagtaaat... | 922       | 9   | ...tttggttag | ...         | 10   |
| 10   | 458       | ...AAAAAAAAA |             |           |     |             |             |      |

Bold *gt* and *ag* were consensus sequences for RNA splicing.

Fig. 2. The typical band patterns of agarose or acrylamide gel electrophoresis. (A) Normal individual genomic DNA amplified using DGGE primer sets for the respective mutation found in exons by duplex PCR. (B) The duplex PCR products from the same genomic DNAs were loaded on a polyacrylamide gel. (C) The aberrant band patterns and sequencing electropherograms of observed SLC22A9 SNPs in osteoporosis and normal subjects. The synonymous A645G, G1449T and C1467T were found in exon 3 and 9, respectively. The G767A, T1277C and C1487T were found in exon 4, 7 and 9, respectively.
Among these six SNPs, two SNPs were found in osteoporosis patients (one in exon 3 and the other in exon 7), three SNPs were found in exon 9 of normal subject and one SNP was found in both osteoporosis patients and normal subjects (exon 4). In order to further clarify this, nucleotide sequencing was performed. As shown in Fig. 2C, the SNPs found from exon 5, 7 and 9 showed that G in the 767th nucleotide of the coding region was changed to A (arginine to glutamine), T in the 1277th nucleotide of the coding region was changed to C (phenylalanine to serine) and C in the 1487th nucleotide of the coding region was changed to T (proline to leucine), respectively. However, other SNPs did not change the amino acid sequences.

Functional analysis of human SLC22A9 variant in Xenopus oocytes

In order to examine whether the SLC22A9 polymorphism found in Korean osteoporosis patients affects the functional activity on substrate transport, we constructed mutant cDNAs and expressed them into Xenopus oocytes. As shown in Fig. 3, F426S exhibited reduced uptake for [3H]estrone sulfate compared with that of the wild-type SLC22A9. R256Q and P496L did not show a statistically significant change in [3H] estrone sulfate compared with those of the wild-type SLC22A9. According to the changes of concentration-dependent [3H] estrone sulf ate in wild type and F426S, the Km values for wild-type and F426S were 0.7 and 1.2 μM, respectively, and the Vmax values for wild-type and F426S were 1.8 and 0.47 pmol/oocyte/h, respectively (Fig. 3).

DISCUSSION

In the present study, the genetic feature of the SLC22A9 was investigated in the Korean women osteoporosis patients and normal subjects. We identified six SNPs (A645G, G767A, T1277C, G1449T, C1467T and C1487T) of SLC22A9 coding region from the osteoporosis and control subjects. Totally 3082 SNPs are reported in the National Center for Biotechnology Information (NCBI) data base. Among them, 1,335 synonymous and non-synonymous SNPs are observed in coding regions. They consist of 68 missense mutations and three stop codon gained mutation within the coding region. In order to understand the characteristics of SLC22A9, ares not yet reported in the NCBI data base. In conclusion, we reported for the first time the nsSNPs of SLC22A9 in Korean women with osteoporosis patients and normal controls. Unfortunately, there is no information of any functional analysis with discovered nsSNP. Our functional analysis showed the increased value in Km (wild type, 8.84 μM vs. F426S, 12.74 μM) and decreased value in Vmax (wild type, 1.97 pmol/oocyte/h vs. F426S, 1.55 pmol/oocyte/h) in estrone sulfate transport. The transporting activities of the other two nsSNPs (R256Q and P496L) are similar to those of wild type SLC22A9.

In human, the functional properties of transport have been reported. With respect to substrate specificity, hOAT3 (SLC22A8) and hOAT4 (SLC22A11) also transport estrone and dehydroepiandrosterone sulfate. The differences between hOAT3, hOAT4 and SLC22A9 are the expression pattern in organ. The expression of OAT3 was observed in brain, skeletal muscle and kidney [13]. The OAT4 message was observed in kidney and placenta [15]. In contrast, SLC22A9 was expressed exclusively in liver [14]. The result of our ongoing study using Saos-2 and MG-63 osteosarcoma cell line showed the expression of SLC22A11 (hOAT4) and SLC22A9 (hOAT7) by polymerase chain reaction (data not shown). From these results, it might be thought of as indirect evidence of steroid sulfate conjugate transport in bone. When we screened the SNPs of SLC22A8 using the same patient blood samples, no nsSNP was found. In the case of SLC22A11 (hOAT4), we have found one nsSNP and have reported the functional change of transporting activity of the mutant (E278K) in independent osteoporosis patients [20]. In order to understand the characteristics of SLC22A9, 9 and 11, the study using cells derived from primary cultured or immortalized cells was necessary.

Several transporter proteins such as the multidrug resistance associated protein [27,28], organic anion transporting polypeptide C [29,30], Na+-taurocholate cotransporting polypeptide [31,32] and the breast cancer resistance protein (BCRP/ABCG2) [33,34] also transport steroids or their sulfate conjugates and their nsSNPs also showed a decrease of their substrate transporting activities [35-38]. It has also reported that nsSNPs showing altered activity in some transporters is co-related with certain disease [39,40]. In addition, several reports revealed that some SNPs of SLC22A8 and SLC22A11 are located in the promoter site [41]. NCBI data base also shows some upstream SNP. The study on the regulatory effect of upstream SNP will be also necessary.

In conclusion, we reported for the first time the nsSNPs of SLC22A9 in Korean women with osteoporosis and verified altered activity that may contribute to understanding certain diseases including osteoporosis.

ACKNOWLEDGEMENT

This work was supported by the National Research Foundation of Korea (NRF-2011-0023984).

REFERENCES

1. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr

SNPs of SLC22A9 in Osteoporosis Patients

323
16. Deighton CM, Walker DJ, Griffiths ID, Roberts DF.
15. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Shin HJ, Anzai N, Enomoto A, He X, Kim do K, Endou H, Kanai
14. Hawkins RA, Perkins AJ, Zhou L, Longcope C, Econs MJ, Peacock M, McClintock C, Johnston CC Jr. Bone loss at the femoral neck in premenopausal white women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2206-2274.
13. Compston JE. Sex steroids and bone. Physiol Rev. 2001;81:419-447.
12. Noel CT, Reed MJ, Jacobs HS, James VH. Bone turnover and sex hormone levels. J Clin Endocrinol Metab. 2002;87:1539-1543.
11. Roberts KD, Rochefort JG, Bleau G, Chapdelaine A. Plasma estrone sulfate levels in postmenopausal women: a lack of diurnal variation, effect of ovariectomy, age and weight. J Steroid Biochem. 1981;14:1101-1105.
10. Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, Tai PJ. Estrogens: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab. 1998;84:4677-4694.
9. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Boyle WJ, Simonet WS, Lacey DL. Osteoporosis and estrogens get very close to each other. J Bone Miner Res. 2002;17:563-566.
8. Evseenko DA, Paxton JW, Keelan JA. ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1367-1365.
7. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Boyle WJ, Simonet WS, Lacey DL. Osteoporosis and estrogens get very close to each other. J Bone Miner Res. 2002;17:563-566.
6. Evseenko DA, Paxton JW, Keelan JA. ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1367-1365.
5. Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, Tai PJ. Estrogens: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab. 1998;84:4677-4694.
4. Evseenko DA, Paxton JW, Keelan JA. ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1367-1365.
3. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Boyle WJ, Simonet WS, Lacey DL. Osteoporosis and estrogens get very close to each other. J Bone Miner Res. 2002;17:563-566.
2. Klareskog L, Padyukov L, Lorentzen J, Alfredsson L. Hypophosphatasia. Mol Genet Metab. 2002;75:143-153.
1. Whi Y, Hayes VM, Oisinga J, Mulder IM, Looman MW, Buys
40. Jamroziak K, Balcerzak E, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szüugielska-Kaplon A, Mirowski M, Bates SE, Robak T. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. *Pharmacol Rep.* 2006;58:720-728.

41. Ogasawara K, Terada T, Motohashi H, Asaka J, Aoki M, Katsura T, Kambe T, Ogawa O, Inui K. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. *J Hum Genet.* 2006;53:607-614.